<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rodriguez-Alfonso A</submitter><funding>Deutsche Forschungsgemeinschaft</funding><funding>Ulm University</funding><funding>German Research Foundation (DFG)</funding><funding>Baden-Württemberg Stiftung</funding><funding>University of Ulm</funding><pagination>15029</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9735595</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(23)</volume><pubmed_abstract>Advanced derivatives of the &lt;b>E&lt;/b>ndogenous &lt;b>P&lt;/b>eptide &lt;b>I&lt;/b>nhibitor of C&lt;b>X&lt;/b>CR&lt;b>4&lt;/b> (EPI-X4) have shown therapeutic efficacy upon topical administration in animal models of asthma and dermatitis. Here, we studied the plasma stability of the EPI-X4 lead compounds WSC02 and JM#21, using mass spectrometry to monitor the chemical integrity of the peptides and a functional fluorescence-based assay to determine peptide function in a CXCR4-antibody competition assay. Although mass spectrometry revealed very rapid disappearance of both peptides in human plasma within seconds, the functional assay revealed a significantly higher half-life of 9 min for EPI-X4 WSC02 and 6 min for EPI-X4 JM#21. Further analyses demonstrated that EPI-X4 WSC02 and EPI-X4 JM#21 interact with low molecula</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.</pubmed_title><pmcid>PMC9735595</pmcid><funding_grant_id>EXC 2033 - 390677874 614 - RESOLV</funding_grant_id><funding_grant_id>CRC1279</funding_grant_id><funding_grant_id>MU 3115/8-1</funding_grant_id><funding_grant_id>L.SBN.0209</funding_grant_id><funding_grant_id>3115/11-1</funding_grant_id><funding_grant_id>436586093</funding_grant_id><funding_grant_id>EXC 2033—390677874—RESOLV</funding_grant_id><funding_grant_id>BWST_WSF-025</funding_grant_id><pubmed_authors>Kuan SL</pubmed_authors><pubmed_authors>Weil T</pubmed_authors><pubmed_authors>Munch J</pubmed_authors><pubmed_authors>Ruiz-Blanco YB</pubmed_authors><pubmed_authors>Standker L</pubmed_authors><pubmed_authors>Wiese S</pubmed_authors><pubmed_authors>Sanchez-Garcia E</pubmed_authors><pubmed_authors>Heck A</pubmed_authors><pubmed_authors>Gilg A</pubmed_authors><pubmed_authors>Harms M</pubmed_authors><pubmed_authors>Rodriguez-Alfonso A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Advanced EPI-X4 Derivatives Covalently Bind Human Serum Albumin Resulting in Prolonged Plasma Stability.</name><description>Advanced derivatives of the &lt;b>E&lt;/b>ndogenous &lt;b>P&lt;/b>eptide &lt;b>I&lt;/b>nhibitor of C&lt;b>X&lt;/b>CR&lt;b>4&lt;/b> (EPI-X4) have shown therapeutic efficacy upon topical administration in animal models of asthma and dermatitis. Here, we studied the plasma stability of the EPI-X4 lead compounds WSC02 and JM#21, using mass spectrometry to monitor the chemical integrity of the peptides and a functional fluorescence-based assay to determine peptide function in a CXCR4-antibody competition assay. Although mass spectrometry revealed very rapid disappearance of both peptides in human plasma within seconds, the functional assay revealed a significantly higher half-life of 9 min for EPI-X4 WSC02 and 6 min for EPI-X4 JM#21. Further analyses demonstrated that EPI-X4 WSC02 and EPI-X4 JM#21 interact with low molecula</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-04-08T11:58:34.924Z</modification><creation>2025-04-19T12:16:18.078Z</creation></dates><accession>S-EPMC9735595</accession><cross_references><pubmed>36499357</pubmed><doi>10.3390/ijms232315029</doi></cross_references></HashMap>